Lataa...
SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)
INTRODUCTION: The PI3K/Akt/mTOR pathway is activated in a majority of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral mTOR inhibitor, in patients with unresectable MPM. METHODS: MPM patients who had received at least one but no more than two prior chemotherapy...
Tallennettuna:
| Julkaisussa: | J Thorac Oncol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304604/ https://ncbi.nlm.nih.gov/pubmed/25611229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000360 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|